Korean J Pain.  2023 Jan;36(1):4-10. 10.3344/kjp.22391.

Current scenario and future applicability of antivirals against herpes zoster

• Kim SH

• KMID: 2537610
• DOI: http://doi.org/10.3344/kjp.22391

Abstract

Herpes zoster (HZ) is a common disease in the aging population and immunocompromised individuals, with a lifetime risk of 20%–30% that increases with age. HZ is caused by reactivation of the varicella-zoster virus (VZV), which remains latent in the spinal dorsal root ganglia and cranial sensory ganglia after resolution of the primary VZV infection. The main focus of HZ management is rapid recovery from VZV infection as well as the reduction and prevention of zoster-associated pain (ZAP) and postherpetic neuralgia (PHN). The use of antivirals against VZV is essential in the treatment of HZ. However, limited antivirals are only licensed clinically for the treatment of HZ, including acyclovir, valacyclovir, famciclovir, brivudine, and amenamevir. Fortunately, some new antivirals against different types of Herpesviridae have been investigated and suggested as novel drugs against VZV. Therefore, this review focuses on discussing the difference in efficacy and safety in the currently licensed antivirals for the treatment of HZ, the applicability of future novel antivirals against VZV, and the preventive or therapeutic effects of these antivirals on ZAP or PHNh

Keyword

Acyclovir; Amenamevir; Antiviral Agents; ASP2151; Brivudine; Famciclovir; Herpes Zoster; Herpesvirus 3, Human; Neuralgia; Postherpetic; Valacyclovir; Varicella Zoster Virus Infection

Reference

1. Jeon YH. 2015; Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. Korean J Pain. 28:177–84. DOI: 10.3344/kjp.2015.28.3.177. PMID: 26175877. PMCID: PMC4500781.

2. Cohen EJ, Jeng BH. 2021; Herpes zoster: a brief definitive review. Cornea. 40:943–9. DOI: 10.1097/ICO.0000000000002754. PMID: 34029242. PMCID: PMC8249351.

3. Marra F, Parhar K, Huang B, Vadlamudi N. 2020; Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 7:ofaa005. DOI: 10.1093/ofid/ofaa005. PMID: 32010734. PMCID: PMC6984676.

4. Patil A, Goldust M, Wollina U. 2022; Herpes zoster: a review of clinical manifestations and management. Viruses. 14:192. DOI: 10.3390/v14020192. PMID: 35215786. PMCID: PMC8876683. PMID: 809240785c8742518811a34b04e15b8d.

5. Majewska A, Mlynarczyk-Bonikowska B. 2022; 40 Years after the registration of acyclovir: do we need new anti-herpetic drugs? Int J Mol Sci. 23:3431. DOI: 10.3390/ijms23073431. PMID: 35408788. PMCID: PMC8998721. PMID: b19f4b5d3b704db9981dc87624502381.

6. Friesen KJ, Alessi-Severini S, Chateau D, Falk J, Bugden S. 2016; The changing landscape of antiviral treatment of herpes zoster: a 17-year population-based cohort study. Clinicoecon Outcomes Res. 8:207–14. DOI: 10.2147/CEOR.S102243. PMID: 27284258. PMCID: PMC4881923.

7. De Clercq E. 2022; FV-100 for the treatment of varicella-virus (VZV) infections: quo vadis? Viruses. 14:770. DOI: 10.3390/v14040770. PMID: 35458500. PMCID: PMC9028626. PMID: f020c1481db64111bd851b7e0bea6164.

8. Andrei G, Snoeck R. 2021; Advances and perspectives in the management of varicella-zoster virus infections. Molecules. 26:1132. DOI: 10.3390/molecules26041132. PMID: 33672709. PMCID: PMC7924330. PMID: c0777c47f3fa48e885bef5378309d440.

9. Tyring SK, Plunkett S, Scribner AR, Broker RE, Herrod JN, Handke LT, et al. 2012; Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial. J Med Virol. 84:1224–32. DOI: 10.1002/jmv.23329. PMID: 22711350.

10. De SK, Hart JC, Breuer J. 2015; Herpes simplex virus and varicella zoster virus: recent advances in therapy. Curr Opin Infect Dis. 28:589–95. DOI: 10.1097/QCO.0000000000000211. PMID: 26524331.

11. Zhu J, Luo G, He Q, Yao M. 2022; Evaluation of the efficacy of unipolar and bipolar spinal dorsal root ganglion radiofrequency thermocoagulation in the treatment of postherpetic neuralgia. Korean J Pain. 35:114–23. DOI: 10.3344/kjp.2022.35.1.114. PMID: 34966018. PMCID: PMC8728553.

12. Singh G, Song S, Choi E, Lee PB, Nahm FS. 2020; Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia. Korean J Pain. 33:201–7. DOI: 10.3344/kjp.2020.33.3.201. PMID: 32606264. PMCID: PMC7336348.

13. Kim SY, Kim DG, Park YM, Jeon YH. 2017; Psoas compartment block for treatment of motor weakness and pain following herpes zoster. Korean J Pain. 30:62–5. DOI: 10.3344/kjp.2017.30.1.62. PMID: 28119773. PMCID: PMC5256265.

14. Poole CL, James SH. 2018; Antiviral therapies for herpesviruses: current agents and new directions. Clin Ther. 40:1282–98. DOI: 10.1016/j.clinthera.2018.07.006. PMID: 30104016. PMCID: PMC7728158.

15. Sauerbrei A. 2016; Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections. Eur J Clin Microbiol Infect Dis. 35:723–34. DOI: 10.1007/s10096-016-2605-0. PMID: 26873382.

16. Yaldiz M, Solak B, Kara RO, Cosansu N, Erdem MT. 2018; Comparison of famciclovir, valaciclovir, and brivudine treatments in adult immunocompetent patients with herpes zoster. Am J Ther. 25:e626–34. DOI: 10.1097/MJT.0000000000000436. PMID: 26808358.

17. Piret J, Boivin G. 2016; Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Curr Opin Infect Dis. 29:654–62. DOI: 10.1097/QCO.0000000000000288. PMID: 27306564.

18. Muhaj FF, George SJ, Nguyen CD, Tyring SK. 2022; Antimicrobials and resistance part II: antifungals, antivirals, and antiparasitics. J Am Acad Dermatol. 86:1207–26. DOI: 10.1016/j.jaad.2021.11.065. PMID: 35122895.

19. Shiraki K, Yasumoto S, Toyama N, Fukuda H. 2021; Amenamevir, a helicase-primase inhibitor, for the optimal treatment of herpes zoster. Viruses. 13:1547. DOI: 10.3390/v13081547. PMID: 34452412. PMCID: PMC8402822. PMID: 7ac596772a52432e9501af3c04093aaf.

20. Pott Junior H, de Oliveira MFB, Gambero S, Amazonas RB. 2018; Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults. Int J Infect Dis. 72:11–5. DOI: 10.1016/j.ijid.2018.04.4324. PMID: 29746903.

21. Whitley RJ, Volpi A, McKendrick M, Wijck A, Oaklander AL. 2010; Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol. 48 Suppl 1:S20–8. DOI: 10.1016/S1386-6532(10)70005-6. PMID: 20510264.

22. Yeh CH, Chang KS, Huang SS, Tsay SL, Tsai JM, Wang YJ. 2022; Comparing prodrugs with acyclovir for treating postherpetic neuralgia among herpes zoster patients: a systematic review and meta-analysis. Healthcare (Basel). 10:1181. DOI: 10.3390/healthcare10071181. PMID: 35885708. PMCID: PMC9322848. PMID: cdf918ce8f454bd89cc61d61d3753c01.

23. Ono F, Yasumoto S, Furumura M, Hamada T, Ishii N, Gyotoku T, et al. 2012; Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster. J Dermatol. 39:902–8. DOI: 10.1111/j.1346-8138.2012.01584.x. PMID: 22670895.

24. Schuster AK, Harder BC, Schlichtenbrede FC, Jarczok MN, Tesarz J. 2016; Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. Cochrane Database Syst Rev. 11:CD011503. DOI: 10.1002/14651858.CD011503.pub2. PMID: 27841441. PMCID: PMC6464932.

25. Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imafuku S, et al. 2017; Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study. J Dermatol. 44:1219–27. DOI: 10.1111/1346-8138.13948. PMID: 28681394. PMCID: PMC5697646.

26. Werner RN, Nikkels AF, Marinović B, Schäfer M, Czarnecka-Operacz M, Agius AM, et al. 2017; European consensus-based (S2k) guideline on the management of herpes zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 2: treatment. J Eur Acad Dermatol Venereol. 31:20–9. DOI: 10.1111/jdv.13957. PMID: 27579792.

27. Stankus SJ, Dlugopolski M, Packer D. 2000; Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician. 61:2437–44. 2447–8. DOI: 10.1517/14656566.5.3.551. PMID: 10794584.

28. Saguil A, Kane S, Mercado M, Lauters R. 2017; Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 96:656–63. PMID: 29431387.

29. John AR, Canaday DH. 2017; Herpes zoster in the older adult. Infect Dis Clin North Am. 31:811–26. DOI: 10.1016/j.idc.2017.07.016. PMID: 29079160. PMCID: PMC5724974.

30. Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. 2014; Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. (2):CD006866. DOI: 10.1002/14651858.CD006866.pub3. PMID: 24500927.

31. Kim J, Kim MK, Choi GJ, Shin HY, Kim BG, Kang H. 2021; Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis. Korean J Pain. 34:509–33. DOI: 10.3344/kjp.2021.34.4.509. PMID: 34593669. PMCID: PMC8494957.

32. Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, et al. 2017; FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: a randomized-controlled trial. J Med Virol. 89:1255–64. DOI: 10.1002/jmv.24750. PMID: 27943311. PMCID: PMC6139434.